Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.72 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794855 | 0.92 | TACR1 (0.75) | TACR1PDE4AKCNH2 | |
| SCHEMBL7785041 | 0.91 | TACR1 (0.76) | TACR1PDE4A | |
| SCHEMBL6795274 | 0.91 | TACR1 (0.76) | TACR1PDE4A | |
| SCHEMBL6788478 | 0.91 | TACR1 (0.78) | TACR1PDE4AALDH1A1MEN1KMT2A | |
| SCHEMBL7783688 | 0.91 | TACR1 (0.78) | TACR1PDE4AALDH1A1MEN1KMT2A | |
| SCHEMBL6794219 | 0.91 | TACR1 (0.78) | TACR1PDE4AALDH1A1MEN1KMT2A | |
| SCHEMBL6796879 | 0.89 | TACR1 (0.73) | TACR1PDE4A | |
| SCHEMBL7785047 | 0.89 | TACR1 (0.73) | TACR1PDE4A | |
| SCHEMBL6795983 | 0.88 | TACR1 (0.82) | TACR1PDE4A | |
| SCHEMBL7785158 | 0.88 | TACR1 (0.82) | TACR1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058914-A1 | Combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040023843-A1 | Preventives/remedies for emotional disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1352659-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1323429-A1 | PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023843-A1 | Preventives/remedies for emotional disorders | MTNR1A, KISS1R, MTNR1B | TACR1 12/4885PDE4A 419/4885KCNH2 894/4885 |
| US-20040058914-A1 | Combination drugs | CHRNA1, CHRNA2, CHRM2 | TACR1 39/4885PDE4A 3474/4885KCNH2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.